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doi:10.1016/j.jtcvs.2006.06.044bjectives: Extrapleural pneumonectomy is a therapeutic option for selected pa-
ients with malignant pleural mesothelioma. The impact of lymph node metastasis
n the site of recurrence and the role of mediastinoscopy in the selection of patients
or extrapleural pneumonectomy, however, remain unclear.
ethods: We reviewed 50 consecutive patients undergoing extrapleural pneumo-
ectomy for malignant pleural mesothelioma in our institution between January
993 and March 2005.
esults: The median survival was 11 months, with a 3-year survival of 24%.
urvival was significantly worse for patients with N2 disease than for those with no
ymph node metastasis (median survival 10 months vs 29 months, respectively, P
005). Patient sex, histologic cell type, stage, and N2 disease, but not mediastinos-
opy, had significant impacts on survival according to univariate analysis. In a
ultivariate analysis, however, only the presence of N2 disease remained a signif-
cant predictor of poor outcome. The proportion of patients with N2 disease and the
ong-term survival was similar regardless of whether preoperative mediastinoscopy
ielded a negative result. The initial site of recurrence was determined in 28 patients
locoregional in 10 and distant in 18). The presence of N2 disease had no impact on
he site of recurrence. Adjuvant hemithoracic radiation therapy, however, signifi-
antly decreased the risk of locoregional recurrence.
onclusions: The presence of N2 disease negatively affects the prognosis of patients
ith malignant pleural mesothelioma. Mediastinoscopy, however, seems to have a
imited role in patient selection for extrapleural pneumonectomy. Adjuvant hemithoracic
adiation therapy but not N2 disease affects the risk of locoregional recurrence.
alignant pleural mesothelioma (MPM) is an uncommon neoplasm asso-
ciated with poor prognosis. The median survival from the time of histo-
logic diagnosis is approximately 12 months.1 The prognosis is worse for
atients with extensive disease, poor performance status, or sarcomatoid histologic
ndings.2 Patients first seen with lymph node metastases have also been reported to
ave poorer prognosis.3 The impact of lymph node metastasis on the site of
ecurrence and the role of mediastinoscopy in the selection of patients for surgery,
owever, remain unclear. We therefore reviewed our experience of patients under-
oing extrapleural pneumonectomy for MPM to assess the impact of lymph node
etastasis on locoregional recurrence and the value of mediastinoscopy for patient
election.
atients and Methods
total of 50 consecutive patients with biopsy-proven MPM underwent extrapleural pneu-onectomy in our institution between January 1993 and March 2005. Most patients (70%, n
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G
TS35) were operated on between June 2001 and March 2005. A
etrospective chart review was performed after approval by the
nstitutional review board.
All patients were evaluated preoperatively by chest radiograph,
ontrast-enhanced computed tomography (CT) of the chest and
bdomen, spirometry, and ventilation-perfusion scan. Magnetic
esonance imaging was used in selected cases. Brain CT or mag-
etic resonance imaging as well as bone scan were performed if
linically indicated. Resectability was defined by tumor confined
o one hemithorax with no evidence of mediastinal organ, spine,
iffuse chest wall involvement, or transdiaphragmatic extension.
ositron-emission tomography was not available in our institution
ntil recently and was not performed for any of these cases.
Mediastinoscopy was always performed if the mediastinal
ymph nodes were at least 1.5 cm in their greatest diameter on the
hest CT. If lymph nodes were smaller than 1.5 cm in their largest
iameter, mediastinoscopy was performed on a case-by-case basis,
ainly according to the surgeon’s preference. Mediastinoscopy
as performed in a standard fashion as previously described4 and
as intended to systematically sample ipsilateral and contralateral
ymph nodes of the upper mediastinum (upper paratracheal, lower
aratracheal, and subcarinal stations). Patients with small (1.5
m in greatest diameter on chest CT) metastatic ipsilateral medi-
stinal lymph nodes found at mediastinoscopy were not necessar-
ly excluded from surgery because these nodal stations were in-
luded in the postoperative hemithoracic radiation field.
Induction chemotherapy and adjuvant postoperative hemitho-
acic radiation have been systematically considered since June
000 for patients undergoing extrapleural pneumonectomy for
PM in our institution. The protocol did not require systematic
ediastinoscopy; if performed, however, the mediastinoscopy was
sually done at the end of the chemotherapy, before the extrapleu-
al pneumonectomy. Extrapleural pneumonectomy included en
loc resection of the lung, parietal pleura, ipsilateral diaphragm,
nd ipsilateral pericardium. Previous biopsy sites were removed,
ith a limited chest wall resection. Systematic mediastinal lymph
ode dissection or sampling was performed in all cases to allow
ccurate surgical staging of the disease. Paraesophageal, peridi-
phragmatic, and subcarinal nodal stations were examined for
umors located on the right and on the left side. Additionally,
aratracheal nodes were examined for right-sided tumors, whereas
ortopulmonary window and para-aortic nodes were sampled for
eft-sided tumors.
Metastases to intrapulmonary, peribronchial, and hilar lymph
odes located within the pleural envelope were defined as N1
isease, whereas all metastases to ipsilateral lymph nodes located
utside the pleural reflection were defined as N2 disease. Con-
ralateral or supraclavicular lymph node metastasis was defined as
3 disease. The nomenclature used for non–small cell lung cancer
nd esophageal cancer was applied to define the location of ex-
Abbreviations and Acronyms
CT  computed tomography
MPMmalignant pleural mesotheliomarapleural nodes. Tumors were staged according to the staging i
12 The Journal of Thoracic and Cardiovascular Surgery ● Januystem developed by the International Mesothelioma Interest
roup and published by the American Joint Committee on Cancer
nd the International Union Against Cancer.5
Postoperative deaths included all patients who died within 30
ays of surgery or during the same hospitalization. Patients were
ollowed up clinically and radiographically every 3 months with a
hysical examination and a chest radiograph or CT scan of the
hest and upper abdomen. CT scans were always obtained if
ecurrence was suspected. Cytologic or histologic documentation
f disease progression was performed if clinically indicated. Lo-
oregional recurrence was defined as recurrence within the surgi-
al or radiated field. Tumor progression outside the surgical or
adiated field was considered to be distant recurrence. All patients
ere followed up until death or until June 2005.
Results are presented as absolute number and percentage or as
edian and range. Categorical variables were compared by 2
nalysis. Survivals were calculated from the time of extrapleural
neumonectomy by means of life-table analysis. Kaplan-Meier
urves were plotted and compared by using the log-rank test for
nivariate analysis. Variables tested were patient sex (male vs
emale), mediastinoscopy (negative vs positive or not done), his-
ologic type (epithelial vs other), induction chemotherapy (yes vs
o), adjuvant radiation therapy (yes vs no), the presence of N2
isease (yes vs no), and stage (I/II vs III/IV). To avoid overad-
ustment by using too many variables in the multivariate models,
nly factors with a P value less than .2 in the univariate analysis
ere considered in the multivariate analysis. Multivariate analysis
as assessed by logistic regression analysis for categorical vari-
bles and by Cox proportional hazards stepwise model for numeric
ariables. StatView V (SAS Institute, Inc, Cary, NC) was used for
ll analyses.
esults
atient characteristics are presented in Table 1. Most pa-
ients were male and had epithelial cell type. Four patients
ied postoperatively (8%). The causes of death were bron-
hopleural fistula (n  1), cardiac arrhythmia (n  1),
ardiac herniation after right pneumonectomy (n  1), and
spiration pneumonia (n  1).
A total of 29 patients had mediastinoscopy done before
ndergoing extrapleural pneumonectomy. The mediastinos-
opy yielded negative results for metastatic lymph nodes in
6 patients. Three patients underwent extrapleural pneumo-
ectomy despite positive results of mediastinoscopy for
ABLE 1. Characteristics of patients undergoing ex-
rapleural pneumonectomy (n  50)
ge (y, median and range) 58 (21-75)
ender (male/female) 42:8
umor side (right/left) 22:28
athology (epithelial/other) 36:14
ediastinoscopy (yes/no) 29:21
nduction chemotherapy (yes/no) 34:16
djuvant radiation therapy (yes/no) 29:21psilateral mediastinal lymph node metastasis. The medias-
ary 2007
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G
TSinoscopy was performed in the same operative setting as
he extrapleural pneumonectomy in 21 cases (20 of these
atients had induction chemotherapy) and within 6 weeks of
xtrapleural pneumonectomy in 6 cases. Two patients with
egative results of mediastinoscopy underwent induction
hemotherapy followed by extrapleural pneumonectomy 3
onths later.
A total of 21 patients had no evidence of metastatic
ymph nodes on final pathologic examination after ex-
rapleural pneumonectomy, another 8 had N1 disease, and
1 had N2 disease. The locations of N2 lymph nodes
ccording to the tumor side are summarized in Table 2.
atients with N2 disease had tumor in a median of 2
xtrapleural lymph node stations (range 1-4). The subcari-
al station was involved in 10 of 11 patients (91%) with
ight-sided tumors and in 5 of 10 patients (50%) with
eft-sided tumors. Eight patients had N2 disease and no
ntrapleural (N1) node metastasis.
Among 19 patients who had negative results of medias-
inoscopy and underwent extrapleural pneumonectomy
ithin the same operative setting, 9 had no metastatic lymph
odes found on final pathologic examination after ex-
rapleural pneumonectomy (47%), 4 had N1 disease (21%),
nd 6 had N2 disease (32%). In 2 of the patients with N2
isease, the positive extrapleural nodes were not reachable
y mediastinoscopy, whereas in 4 the lymph nodes were
ampled but no metastatic disease was detected on frozen
ection. Subcarinal node biopsies were falsely negative in 3
atients, and the left lower paratracheal lymph node was
alsely negative in 1 patient with a left-sided tumor. The
egative predictive value of mediastinoscopy for extrapleu-
al metastatic lymph nodes was 68%.
The overall median survival was 11 months, with a
-year survival of 24% (Figure 1). Survival was signifi-
antly worse for patients with N2 disease than for those with
o lymph node metastasis (median survival of 10 months vs
ABLE 2. Sites of extrapleural lymph nodes metastasis
bserved in 21 patients with N2 disease after extrapleural
neumonectomy
ymph node station*
Right-sided tumor
(n  11)
Left-sided tumor
(n  10)
pper paratracheal (station 2) 1 (9%) —
ower paratracheal (station 4) 3 (27%) 4 (40%)
ubaortic (station 5) — 4 (40%)
ara-aortic (station 6) — 4 (40%)
ubcarinal (station 7) 10 (91%) 5 (50%)
nterior mediastinal 3 (27%) 1 (10%)
nternal mammary 1 (9%) 1 (10%)
araesophageal 2 (18%) 4 (40%)
Most patients had more than one station involved.9 months, respectively; P  .005). The median survival, d
The Journal of Thoracicowever, was similar between patients with N1 and N2
isease (Figure 2). Among patients with N2 disease, the site
f lymph node metastasis, the number of lymph node sta-
ions involved, or the presence of N2 disease with no
ntrapleural node involvement did not affect survival.
Univariate analysis demonstrated that sex, histologic
ype, N2 disease, and stage had a significant impact on
urvival (Table 3). Female patients and epithelial tumors
ere associated with better survival, whereas N2 disease
nd advanced stage were associated with worse survival.
fter multivariate analysis, however, only N2 disease re-
ained a significant predictor of outcome. A negative result
f preoperative mediastinoscopy had no significant impact
n survival in either the univariate or the multivariate
nalysis.
igure 1. Overall survival of 50 patients undergoing extrapleural
neumonectomy.
igure 2. Survival of patients after extrapleural pneumonectomy
ccording to presence of metastatic lymph nodes. Survival was
ignificantly better for patients without metastatic lymph nodes
han for patients with N1 or N2 disease (P  .005). No difference
n survival was observed between patients with N1 and N2
isease (P  .5).
and Cardiovascular Surgery ● Volume 133, Number 1 113
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G
TSThe frequency of N2 disease diagnosed after extrapleural
neumonectomy was similar between patients who did not
ndergo preoperative mediastinoscopy and those who un-
erwent extrapleural pneumonectomy after negative results
f mediastinoscopy (Table 4). There was also no difference
n the long-term survival between patients who had a neg-
tive mediastinoscopy result immediately before extrapleu-
al pneumonectomy and those who had an extrapleural
neumonectomy without preoperative mediastinoscopy
Figure 3).
The initial site of recurrence was determined in 28 pa-
ients. Four patients had more than one site of recurrent
isease at the time of relapse. Locoregional recurrence
ccurred in 10 patients, abdominal recurrence in 9, recur-
ence in the contralateral chest in 12, and recurrence in the
ericardium in 1. Locoregional recurrence was always lo-
ated within the pleural space (even in patients with N2
isease) and was rarely associated with enlarging medias-
inal nodes (n  1). Adjuvant hemithoracic radiation ther-
py was associated with a significantly lower risk of locore-
ional recurrence in both univariate and multivariate
nalyses (Table 5). Among patients with N2 disease, locore-
ional recurrence was detected in only 1 of 11 patients who
nderwent adjuvant hemithoracic radiation therapy,
hereas it was observed in 5 of 9 patients who did not have
ABLE 4. Frequency of lymph node metastasis in patients
ndergoing extrapleural pneumonectomy with or without
reoperative mediastinoscopy during the same operative
etting
ostoperative nodal
taging
Negative
mediastinoscopy
(n  19)
No
mediastinoscopy
(n  21)
o nodal disease 9 (47%) 11 (52%)
1 disease 4 (21%) 3 (14%)
ABLE 3. Impact of potential prognostic factors on long-
erm survival after extrapleural pneumonectomy by univar-
ate and multivariate analysis (n  46)*
ariable N
Univariate
analysis
P value
Multivariate analysis
P value
95% Confidence
interval
ale patients 39 .008 .09 0.8-19.1
egative mediastinoscopy 23 .2 .7 0.4-1.9
pithelial cell type 33 .006 .09 0.2-1.1
nduction chemotherapy 30 .9 — —
djuvant radiation therapy 29 .7 — —
2 disease 21 .005 .04 1.1-5.2
tage III or IV 38 .03 .8 0.3-3.9
Postoperative deaths (n  4) were excluded from analysis.2 disease 6 (32%) 7 (33%)
14 The Journal of Thoracic and Cardiovascular Surgery ● Janudjuvant radiation (9% vs 56%, respectively, P  .02).
etter locoregional control was associated with a trend
oward improved disease-free survival. Disease-free sur-
ival increased from 4.5 months for patients who did not
ndergo adjuvant hemithoracic radiation to 11 months when
igure 3. Survival was not significantly different between pa-
ients undergoing extrapleural pneumonectomy after negative
esults of mediastinoscopy and those undergoing extrapleural
neumonectomy without mediastinoscopy or after positive re-
ults of mediastinoscopy.
ABLE 5. Impact of potential risk factors on locoregional
nd distant recurrence after extrapleural pneumonectomy
isk factor
Recurrence P value
Local
(n  10)
Distant
(n  18) Univariate Multivariate
ex .2 .9
Male 9 18
Female 1 0
ediastinoscopy .8 —
Negative 5 10
Positive or not done 5 8
istologic type .05 .05
Epithelial 4 14
Other 6 4
nduction chemotherapy .09 .1
Yes 4 13
No 6 5
djuvant radiation
therapy
.008 .01
Yes 2 13
No 8 5
odal disease .9 —
N0 or N1 4 7
N2 6 11
tage .6 —
I or II 1 3
III or IV 9 15
ary 2007
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G
TSemithoracic radiation was administered after extrapleural
neumonectomy (P  .1).
iscussion
his study supports previous publications demonstrating the
egative impact of lymph node metastasis on outcome in
atients with MPM. The 3-year survival reached 47% for
atients without nodal metastasis, whereas it was only 10%
or patients with N2 disease. There was no significant dif-
erence in median survival between patients with N1 and N2
isease. Although the number of patients is small, this
nding supports the current TNM staging system published
y the American Joint Committee on Cancer and Interna-
ional Union Against Cancer, which groups N1 and N2 node
etastases as stage III disease.
The frequency in the literature of nodal metastasis in
atients undergoing surgery for MPM varies between 25%
nd 57%.3,6,7 Our experience is similar to that reported in
he literature, with a frequency of approximately 50%. The
arge majority of metastatic nodes in our series were located
utside the pleural reflection. Few patients had intrapleural
ode metastasis only. As reported by other authors, subcari-
al and paratracheal nodes are frequent sites of extrapleural
etastasis.6,8 Metastasis to lymph nodes inaccessible by
ediastinoscopy, however, such as the internal mammary
hain, the anterior mediastinum, the aortopulmonary win-
ow, or the paraesophageal region, is also often seen.3,8
In our experience, the proportion of patients with meta-
tatic lymph nodes after extrapleural pneumonectomy was
imilar regardless of whether the patients underwent preop-
rative mediastinoscopy. This finding can be explained by
he rate of false-negative biopsy results from subcarinal and
aratracheal nodes at the time of mediastinoscopy and by
he presence of metastatic lymph nodes at stations inacces-
ible by mediastinoscopy.
The value of mediastinoscopy in patients with MPM was
reviously analyzed in two reports.9,10 Schouwink and col-
eagues9 observed that among 25 patients undergoing ex-
rapleural pneumonectomy after negative mediastinoscopy
esults, 9 patients (36%) were found to have N2 disease.9 In
patients the lymph nodes were not accessible by medias-
inoscopy, and in 3 the low paratracheal and subcarinal
ymph nodes were sampled but turned out to be positive
nly after the extrapleural pneumonectomy.9 Rice and as-
ociates10 reported that of 14 patients with positive ipsilat-
ral mediastinal nodes after extrapleural pneumonectomy,
nly 5 were correctly identified preoperatively by medias-
inoscopy. Thus, similar to our experience, approximately a
hird of the patients were found to have N2 disease after
xtrapleural pneumonectomy despite a negative result of
ediastinoscopy.
Preoperative mediastinoscopy in patients who are other-ise candidates for extrapleural pneumonectomy can detect i
The Journal of Thoracic2 disease in about 15% of the patients and N3 disease in
bout 4%.9,10 Mediastinoscopy detected 10 cases of N2
isease among 62 patients (16%) evaluated for extrapleural
neumonectomy in the study reported by Rice and associ-
tes10 and 6 of 43 (14%) in the study reported by Schouwink
nd colleagues.9 Rice and associates10 also found 4 patients
ith N3 disease at mediastinoscopy among 111 patients
valuated for extrapleural pneumonectomy (3.6%).
The role of extrapleural pneumonectomy for patients
ith mediastinal lymph node metastasis is still controver-
ial.6,9,10 Although the median survival after extrapleural
neumonectomy is only 10 to 12 months for patients with
2 disease, in our experience, and in that of others,9,11 some
atients are still alive and disease free more than 3 years
fter surgery despite the presence of N2 disease. In addition,
he introduction of postoperative hemithoracic radiation
herapy can achieve excellent locoregional control even in
atients with N2 disease.11
In our experience, approximately 35% of the patients had
ocoregional recurrence after extrapleural pneumonectomy.
e observed, however, that adjuvant hemithoracic radiation
herapy after extrapleural pneumonectomy significantly de-
reased the risk of locoregional recurrence, particularly
hen administered to patients with N2 disease. Fewer than
0% of the patients with N2 disease had locoregional re-
urrence if radiation therapy was administered postopera-
ively, whereas the rate was greater than 50% among pa-
ients with N2 disease who did not undergo adjuvant
adiation.
There is no doubt that additional research is needed to
mprove our ability to adequately select candidates for ex-
rapleural pneumonectomy. Standard cervical mediastinos-
opy alone seems to have a limited role to improve this task;
owever, we acknowledge that our study is limited by the
mall total number of patients. The combination of medi-
stinoscopy with laparoscopy and possibly with contralat-
ral thoracoscopy may increase the accuracy of staging.10,12
ggressive mediastinoscopy with large sampling of the
ubcarinal nodes may also be important to improve the
ccuracy of mediastinoscopy, because station 7 is positive
n a large proportion of patients with N2 disease. Positron-
mission tomography may have a role in patient selection in
he future but seems more reliable to detect extrathoracic
etastases than mediastinal nodal disease.13
In conclusion, the presence of N2 disease negatively
ffects the long-term survival of patients with MPM. Me-
iastinoscopy, however, seems to have a limited role in
atient selection for extrapleural pneumonectomy. In addi-
ion, the administration of adjuvant hemithoracic radiation
herapy appears to improve local control after extrapleural
neumonectomy, particularly for patients with N2 disease.
lthough there appears to be little indication currently forncluding mediastinoscopy in the treatment protocol of
and Cardiovascular Surgery ● Volume 133, Number 1 115
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TSPM, in the future, if stage-dependent treatment protocols
re conceived, mediastinoscopy, in addition to other staging
odalities, may become a more critical staging tool.
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